FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4224284920> ?p ?o ?g. }

• W4224284920 endingPage "S13" @default.
• W4224284920 startingPage "S12" @default.
• W4224284920 abstract "<h3>Purpose</h3> We describe Advanced Cardiac Therapies Improving Outcomes Network (ACTION) pediatric multicenter experience with Impella® percutaneous ventricular assist device (PVAD) support for management of cardiogenic shock. <h3>Methods</h3> Retrospective review of patients supported with a Impella PVAD 15 pediatric centers participating in ACTION Collaborative from 10/2014 to 09/2021. Only patients supported with Impella PVAD alone were included. Demographics, device, and outcomes data was reviewed and reported using descriptive statistics. <h3>Results</h3> Total of 47 patients met the inclusion criteria. Median age was 16.1 years (range 6.38,34.4), weight 65.0 kg (range 29.6,124), and BSA 1.75 m² (range 1.05,2.52). PVAD was used most often for transplant graft dysfunction (40.4%) followed by dilated cardiomyopathy/myocarditis (31.9%), end stage congenital heart disease (14.9%) and others (12.5%). INTERMACS Profile 1 was reported in 42.6%, Profile 2 in 42.6%, and Profile 3 in 10.6%. Strategies for support included bridge to recovery (55.3%), bridge to transplant (23.4%) and bridge to decision (19.1%). Ten patients (21.3%) were bridged to durable VAD support. Impella CP was used in 64% cases, 5.0 in 18% and 5.5 in 18%. Nine (19%) patients had >1 device implanted. Anticoagulation was achieved with unfractioned heparin in 91% and a direct thrombin inhibitors in 9%. Median duration of support was 5.5 days (range 1,116) on CP device, 27 days (range 6,64) on 5.5 device and 21.5 days (range 8,143) on 5.0 device. Most common device complications included hemolysis (39.0%), major bleeding (15.3%), device malfunction (13.6%), renal failure (8.5%), arterial non-CNS thrombus (5.1%), and cardiac arrhythmia (3.2%). There were no neurological events. A positive clinical outcome was achieved in 85% of patients (77% survived to explant; 8% alive on device). <h3>Conclusion</h3> This study reports the Impella PVAD pediatric multi center experience for support of cardiogenic shock, with overall low morbidity and satisfactory survival benefit for a high-risk population. This device should be considered as part of the mechanical support armamentarium used in management of cardiogenic shock. Further investigation into optimal patient selection and support environment is needed to optimize its use in pediatric institutions and minimize adverse events." @default.
• W4224284920 created "2022-04-26" @default.
• W4224284920 creator A5002965469 @default.
• W4224284920 creator A5004985576 @default.
• W4224284920 creator A5005398214 @default.
• W4224284920 creator A5014277766 @default.
• W4224284920 creator A5018766924 @default.
• W4224284920 creator A5020047408 @default.
• W4224284920 creator A5024690253 @default.
• W4224284920 creator A5028265749 @default.
• W4224284920 creator A5030675334 @default.
• W4224284920 creator A5042776305 @default.
• W4224284920 creator A5051692878 @default.
• W4224284920 creator A5053663782 @default.
• W4224284920 creator A5055882443 @default.
• W4224284920 creator A5062202338 @default.
• W4224284920 creator A5062695422 @default.
• W4224284920 creator A5070095313 @default.
• W4224284920 creator A5071852921 @default.
• W4224284920 creator A5071990477 @default.
• W4224284920 creator A5074140403 @default.
• W4224284920 creator A5077972688 @default.
• W4224284920 creator A5078535983 @default.
• W4224284920 creator A5079203590 @default.
• W4224284920 creator A5079432854 @default.
• W4224284920 creator A5080167839 @default.
• W4224284920 creator A5081441113 @default.
• W4224284920 creator A5081977294 @default.
• W4224284920 creator A5086110208 @default.
• W4224284920 date "2022-04-01" @default.
• W4224284920 modified "2023-09-27" @default.
• W4224284920 title "Characteristics and Outcomes of Patients Supported with Impella Percutaneous VAD Device at Pediatric Institutions: Action Collaborative Experience" @default.
• W4224284920 doi "https://doi.org/10.1016/j.healun.2022.01.024" @default.
• W4224284920 hasPublicationYear "2022" @default.
• W4224284920 type Work @default.
• W4224284920 citedByCount "1" @default.
• W4224284920 countsByYear W42242849202023 @default.
• W4224284920 crossrefType "journal-article" @default.
• W4224284920 hasAuthorship W4224284920A5002965469 @default.
• W4224284920 hasAuthorship W4224284920A5004985576 @default.
• W4224284920 hasAuthorship W4224284920A5005398214 @default.
• W4224284920 hasAuthorship W4224284920A5014277766 @default.
• W4224284920 hasAuthorship W4224284920A5018766924 @default.
• W4224284920 hasAuthorship W4224284920A5020047408 @default.
• W4224284920 hasAuthorship W4224284920A5024690253 @default.
• W4224284920 hasAuthorship W4224284920A5028265749 @default.
• W4224284920 hasAuthorship W4224284920A5030675334 @default.
• W4224284920 hasAuthorship W4224284920A5042776305 @default.
• W4224284920 hasAuthorship W4224284920A5051692878 @default.
• W4224284920 hasAuthorship W4224284920A5053663782 @default.
• W4224284920 hasAuthorship W4224284920A5055882443 @default.
• W4224284920 hasAuthorship W4224284920A5062202338 @default.
• W4224284920 hasAuthorship W4224284920A5062695422 @default.
• W4224284920 hasAuthorship W4224284920A5070095313 @default.
• W4224284920 hasAuthorship W4224284920A5071852921 @default.
• W4224284920 hasAuthorship W4224284920A5071990477 @default.
• W4224284920 hasAuthorship W4224284920A5074140403 @default.
• W4224284920 hasAuthorship W4224284920A5077972688 @default.
• W4224284920 hasAuthorship W4224284920A5078535983 @default.
• W4224284920 hasAuthorship W4224284920A5079203590 @default.
• W4224284920 hasAuthorship W4224284920A5079432854 @default.
• W4224284920 hasAuthorship W4224284920A5080167839 @default.
• W4224284920 hasAuthorship W4224284920A5081441113 @default.
• W4224284920 hasAuthorship W4224284920A5081977294 @default.
• W4224284920 hasAuthorship W4224284920A5086110208 @default.
• W4224284920 hasConcept C126322002 @default.
• W4224284920 hasConcept C164705383 @default.
• W4224284920 hasConcept C2776850375 @default.
• W4224284920 hasConcept C2778198053 @default.
• W4224284920 hasConcept C2778774980 @default.
• W4224284920 hasConcept C2780574415 @default.
• W4224284920 hasConcept C2780813298 @default.
• W4224284920 hasConcept C2780875844 @default.
• W4224284920 hasConcept C500558357 @default.
• W4224284920 hasConcept C71924100 @default.
• W4224284920 hasConceptScore W4224284920C126322002 @default.
• W4224284920 hasConceptScore W4224284920C164705383 @default.
• W4224284920 hasConceptScore W4224284920C2776850375 @default.
• W4224284920 hasConceptScore W4224284920C2778198053 @default.
• W4224284920 hasConceptScore W4224284920C2778774980 @default.
• W4224284920 hasConceptScore W4224284920C2780574415 @default.
• W4224284920 hasConceptScore W4224284920C2780813298 @default.
• W4224284920 hasConceptScore W4224284920C2780875844 @default.
• W4224284920 hasConceptScore W4224284920C500558357 @default.
• W4224284920 hasConceptScore W4224284920C71924100 @default.
• W4224284920 hasIssue "4" @default.
• W4224284920 hasLocation W42242849201 @default.
• W4224284920 hasOpenAccess W4224284920 @default.
• W4224284920 hasPrimaryLocation W42242849201 @default.
• W4224284920 hasRelatedWork W2004365919 @default.
• W4224284920 hasRelatedWork W2012685426 @default.
• W4224284920 hasRelatedWork W2333914885 @default.
• W4224284920 hasRelatedWork W2474888291 @default.
• W4224284920 hasRelatedWork W2742483429 @default.
• W4224284920 hasRelatedWork W2909699868 @default.
• W4224284920 hasRelatedWork W3047553641 @default.
• W4224284920 hasRelatedWork W3198919412 @default.
• W4224284920 hasRelatedWork W4214761868 @default.

• next